Bot detection and mitigation company Distil Networks has raised a $10 million Series A round of funding. Foundry Group and Techstars’ Bullet Time Ventures led the round, while ff Venture Capital, IDEA Fund Partners and Militello Capital all participated. The funds will be used for continued growth as the company opens new offices across the U.S.
DemystData, which provides real-time customer scoring values for financial institutions, has raised $5 million in a Series A funding round. Notion Capital, Arbor Ventures, SingTel Innov8, P2P Equity Partners and Errol Damelin all participated, as did current investors Arbor Ventures and Accion Venture Lab.
Jobaline.com, a mobile, bilingual hourly-jobs marketplace, has completes a $7 million Series B funding round. Trilogy Equity Partners led the round, while existing investors Madrona Venture Group and Rudy Gadre and new investor Founders Co-op also participated. Jobaline.com was launched in 2013 and has processed more than 400,000 job applications in the markets it currently operates in. “We are helping to address the recruiting crisis that costs the U.S. economy more than $300 billion in inefficiencies in the hourly jobs space while enabling job seekers to complete job applications from any computer, tablet, or phone, even via text messaging,” said Jobaline.com CEO and Chairman Luis J. Salazar.
Acquia, which provides support services for the Dupral social publishing platform, has raised a fresh round of funding worth $50 million. New Enterprise Associates (NEA) led the round, while new investor Split Rock Partners and existing investors North Bridge Venture Partners, Sigma Partners, Investor Growth Capital and Tenaya Capital participated.
Message Bus, a provider of cloud-based email infrastructure, has raised $4 million in funding and has launched its next generation email platform. The funding round was led by True Ventures, while North Bridge Venture Partners and Ignition Partners also participated. The company has raised a total of $18 million in funding to date.
Volcano Corporation, which develops and manufactures precision guided therapy tools for the diagnosis and treatment of coronary and peripheral vascular diseases, has acquired AtheroMed for an initial $115 million in cash. AtheroMed’s main product, The Phoenix, is used in the treatment of peripheral artery disease. Volcano Corporation will make an additional $15 million payment if The Phoenix passes FDA approval.